Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with kasabach-merritt phenomenon

  • Antiaggregants in Kasabach-Merritt phenomenon
  • Israel Fernandez-Pineda, Juan Carlos Lopez-Gutierrez, Gloria Chocarro, Jose Bernabeu-Wittel, Gema Lucia Ramirez-Villar
  • Pediatric Blood & Cancer, April 2013, Wiley
  • DOI: 10.1002/pbc.24543

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1002/pbc.24543

In partnership with:

Link to Wiley showcase

More from this publisher